Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 4/20 | 0.50 |
| ▸ | RXRB | P28702 | 4/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418674 | 0.89 | AOC3 (0.67) | KMT2ANR1H4EPHX2AOC3HDAC1 | |
| SCHEMBL5724620 | 0.85 | LIPG (0.60) | KMT2AAOC3HDAC1LIPGEGFR | |
| SCHEMBL25542634 | 0.84 | LIPG (0.56) | BCL2AOC3HDAC1LIPG | |
| SCHEMBL5445345 | 0.83 | LMNA (0.68) | BCL2KMT2ANR1H4EPHX2AOC3 | |
| SCHEMBL3530258 | 0.83 | KMT2A (0.64) | KMT2ANR1H4HDAC1 | |
| SCHEMBL5549803 | 0.81 | HDAC1 (0.60) | BCL2NR1H4EPHX2AOC3HDAC1 | |
| SCHEMBL23442907 | 0.81 | LIPG (0.54) | BCL2AOC3HDAC1LIPG | |
| SCHEMBL3145591 | 0.81 | AOC3 (0.52) | KMT2AAOC3HDAC1LIPG | |
| SCHEMBL5944011 | 0.80 | HDAC1 (0.61) | BCL2NR1H4EPHX2AOC3HDAC1 | |
| SCHEMBL12894973 | 0.80 | BCL2 (1.00) | BCL2NR1H4EPHX2AOC3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | BCL2 2466/4885KMT2A 1480/4885NR1H4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.